brain cancer

[NOXXON Pharma, Inc.] NOXXON Pharma, Inc. announced that an independent Data Safety Monitoring Board has confirmed that the highest dose of NOX-A12 in combination with radiotherapy in the ongoing Phase I/II study in patients with brain cancer is safe and that the trial should continue as planned.

[D&D Pharmatech, Inc. (Business Wire, Inc.))] D&D Pharmatech, Inc. announced it has entered into a sponsored research agreement with Yale University relating to optimization of two novel approaches that allow immune system cells and drug molecules to bypass the blood-brain barrier for the treatment of brain cancer and other disorders.

[Nature Biomedical Engineering] Researchers showed that a double-network hydrogel could rapidly reprogram differentiated cancer cells into cancer stem cells.

[Nature Communications] Scientists showed that P-selectin mediated microglia-enhanced glioblastoma proliferation and invasion by altering microglia/macrophages activation state.

[British Journal of Cancer] Using glioma patient database and human glioma cells, scientists assessed the mechanisms and function of selective autophagy to sustain mTORC1 hyper-activation in glioma.

[Cytotherapy] The authors classify and critically discuss the technical aspects of MSC-extracellular vesicle (EV) animal studies and discusses potential relationships between methodological details and the effectiveness of MSC-EVs as reported by these pre-clinical studies.